SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tnsaf who wrote (3226)3/21/2019 9:14:30 AM
From: tuck1 Recommendation

Recommended By
Lance Bredvold

  Read Replies (1) of 3661
 
Biogen (BIIB) off 27% pre-market on P3 fail in Alzheimer's. Given the track record of the amyloid hypothesis and the P2 data, it's actually a surprise to me the valuation apparently had that much riding on the program. I don't follow the company much, but this could be a trading buy on the bad news at the end of the session. Not saying I'm going to try that, but it could work. It could also mean BIIB will be hunting for programs to buy . . .

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News